Co‐medication of pravastatin and paroxetine—A categorical study

Keywords

Paroxetine, Pravastatin, Renal function, Medicine, Drug reaction

References

• Type 2 Diabetes Risk Forecasting from EMR Data using Machine LearningSubramani Mani, Yukun Chen, Tom A. Elasy — 2012
• Outliers in Statistical DataW. R. Buckland — 1979
• Statins and new-onset diabetes: a retrospective longitudinal cohort study.Tsochiang Ma, Liyun Tien, Chih-Ling Fang — 2012
• Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives.José M. López‐Novoa, Carlos Martı́nez-Salgado, Ana B. Rodríguez-Peña — 2010
• Outliers in Statistical Data (3rd edition)Jim Freeman — 1995
• Pravastatin Counteracts Angiotensin II-Induced Upregulation and Activation of NADPH Oxidase at Plasma Membrane of Human Endothelial CellsEzequiel Álvarez, Bruno K. Rodiño‐Janeiro, Rafael Ucieda‐Somoza — 2010
• Hyperglycemia Associated with ParoxetineKevin J. Petty — 1996
• Insights into the Redox Control of Blood Coagulation: Role of Vascular NADPH Oxidase-Derived Reactive Oxygen Species in the Thrombogenic CycleOlaf Herkert, Talija Djordjevic, Rachida S. BelAiba — 2004
• Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean CohortVasilios G. Athyros, Evangelos Liberopoulos, Dimitri P. Mikhailidis — 2007
• An Automated Model Using Electronic Medical Record Data Identifies Patients With Cirrhosis at High Risk for ReadmissionAmit G. Singal, Robert S. Rahimi, Christopher Clark — 2013
• Increased cholesterol levels during paroxetine administration in healthy men.Nathalie Lara, Glen B. Baker, Stephen L. Archer — 2003
• The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.JC Bloomer, F. R. Woods, R. E. Haddock — 1992
• Brenner and Rector's The KidneyBarry M. Brenner — 2000
• Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study.Maria B. Ræder, Ingvar Bjelland, Stein Emil Vollset — 2006
• Measuring data reliability for preventive services in electronic medical recordsMichelle Greiver, Jan Barnsley, Richard H. Glazier — 2012
• Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention StudyDilys J. Freeman, John Norrie, Naveed Sattar — 2001
• Weight Loss and Body Mass Index as Predictors of HIV Disease Progression to AIDS in Adults. Aquitaine Cohort, France, 1985–1997Denis Malvy, Rodolphe Thiébaut, Catherine Marimoutou — 2001
• The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides.Michiaki Abe, Takafumi Toyohara, Akiko Ishii — 2010
• Physician use of electronic medical records: Issues and successes with direct data entry and physician productivityPaul D. Clayton, Scott P Naus, Watson Bowes — 2005
• Pravastatin and cardiovascular risk in moderate chronic kidney disease.Haruo Nakamura, Kyoichi Mizuno, Yasuo Ohashi — 2009

Cited by

• Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposureFeng Li, Mian Zhang, Dan Xu — 2014
• Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic ratsFeng Li, Zhaoli Ling, Zhongjian Wang — 2017
• Impact of Muscarinic M3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled StudyYen‐Hao Tran, Catharina C. M. Schuiling‐Veninga, Jorieke E. H. Bergman — 2017
• A Survey of Data Processing of EMR (Electronic Medical Record) Based on Data MiningWencheng Sun, Fang Liu, Zhiping Cai — 2017
• The next generation of drug safety science: coupling detection, corroboration, and validation to discover novel drug effects and drug-drug interactionsNicholas P. Tatonetti — 2018
• Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseasesSiegfried Kasper — 2019
• Clinically relevant drug interactions between statins and antidepressantsCaterina Palleria, Roberta Roberti, Luigi Francesco Iannone — 2020
• The Anti-Depressant Effects of Statins in Patients With Major Depression Post-Myocardial Infarction: An Updated Review 2022Sai Dheeraj Gutlapalli, Hadi Farhat, Huma Irfan — 2022
• Use of electronic health record data for drug safety signal identification: A scoping reviewSharon E. Davis, Luke E. Zabotka, Rishi Desai — 2023
• Związki między stosowaniem statyn a zaburzeniami depresyjnymi oraz zachowaniami samobójczymiAlicja Barbara Roztocka, Karol Radziszewski, Patryk Osiński — 2025
• THE IMPACT OF COMBINED ADMINISTRATION OF SEROTONIN-SPECIFIC REUPTAKE INHIBITORS WITH ATORVASTATIN ON THE LIVER AND KIDNEYS . IN VITRO AND IN VIVO STUDIESMariola Herbet, M. Izdebska, Monika Gawro — 2017

Related papers

• Analysis and nursing care of adverse drug reaction in clinic and emergencySong Ai-mei — 2012
• Assessment of Adverse Drug Reactions reported to the regional Adverse Drug Reaction Monitoring Centre at a tertiary care teaching hospital in Bhopal.Arvind Kumar Sharma, Rakesh Sonawane, Neha Jain — 2015
• Analysis on 5277 cases of adverse drug reactions of traditional Chinese medicineZhu Lingqi — 2010
• The Distinction of Pharmacovigilance with Adverse Drug Reaction MonitoringCai We — 2006
• INVESTIGATION OF ADVERSE DRUG REACTION OF A HOSPITALWenzhu Huang — 2012
• Analysis report for 95 kinds of adverse drug reactionsZhang Jin-lian — 2011
• Analysis on Monitoring Reports of50cases of Adverse Drug Reactions in Our HospitalDU Xiaoqin, YE Cuiying — 2005
• Review of 146 Samples Reported with Adverse Drug ReactionsChangsheng Zhou — 2010
• Analysis on 192 Cases of Adverse Drug Reaction in Our Hospital during 2008 to 2009LI Jing-ling, Peng Feng — 2010